Precirix: The company raised EUR 80 million of Series B venture funding in a deal led by Inkef Capital, Jeito, and Forbion on March 16, 2022. Gimv, HealthCap, Novo Holdings, Pontifax Venture Capital, BioMedPartners, V-Bio Ventures, and other undisclosed investors also participated in the round. The company is a developer of radio-immunotherapeutic drugs designed to offer a new generation of targeted cancer therapies.
Deepcell: The company raised $73 million of Series B venture funding in a deal led by Koch Disruptive Technologies on March 17, 2022. Bow Capital, Andreessen Horowitz, Bridger Healthcare, Horizons Ventures, Jeff Dean, Matt Mcllwain, and Casdin Capital also participated in the round. The company is a developer of a diagnostic biotechnology intended to offer non-invasive genetic tests with diagnostic-level accuracy.
Molecular Assemblies: The company raised $25.8 million of Series B venture funding from Codexis, Agilent Technologies, and iSelect Fund on March 15, 2022. Argonautic Ventures, LYFE Capital, and Casdin Capital also participated in the round. The company is a developer of an enzymatic DNA synthesis technology designed to power next-generation DNA-based products.
House Rx: The company raised $25 million of Series A venture funding in a deal led by Bessemer Venture Partners on March 14, 2022, putting the company’s pre-money valuation at $100 million. First Round Capital, 1984 Ventures, and Character (VC) also participated in the round. The company is a provider of healthcare products and services intended to make specialty medication more accessible and affordable.
BoomerangFX: The company raised an estimated $20 million of Series B venture funding from undisclosed investors on March 15, 2022. The company is a developer of a practice management software intended to streamline business operations.
VideaHealth: The company raised $20 million of venture funding from undisclosed investors on March 18, 2022. The company is a developer of an artificial intelligence technology designed to automatically detect pathologies in dental imaging.
Curiox Biosystems: The company raised $15 million of Series C venture funding in a deal led by Luha Private Equity on March 16, 2022. KB Investment, QUAD Investment Management, and other undisclosed investors also participated in the round. The company is an operator of a bio-instrumentation firm intended to create products based on surface chemistry and engineering.
Nue Life: The company raised $15 million of Series A1 venture funding from undisclosed investors on March 14, 2022, putting the company’s pre-money valuation at $80 million. The company is a developer of a mental wellness application designed to offer at-home ketamine therapy.
restor3d: The company raised $14 million of venture funding from 147 undisclosed investors on March 15, 2022. The company is a developer of 3D printed implants intended to enable surgeons to repair and reconstruct the human body.
Canopy Care: The company raised $13 million of venture funding in a deal led by GSR Ventures on March 17, 2022. Samsung Electronics also participated in the round. The company is a developer of a platform intended to power an entire layer of interoperable software solutions over EMR and practice management systems.
Prevencio: The company raised $8.4 million of venture funding from undisclosed investors on March 16, 2022. The company is a developer of multi-proteomic biomarkers designed to revolutionize blood tests for cardiovascular disease.
KayoThera: The company raised $8 million of Series A venture funding from Accelerator Life Science Partners, BioAdvance, and 7G Bioventures on March 17, 2022. The company is a developer of immune and targeted therapies designed to cure late-stage and metastatic cancers.
Kogniz: The company raised $7.5 million of venture funding from undisclosed investors on March 18, 2022. The company is a developer of an artificial intelligence-enabled health response platform designed to offer end-to-end workplace safety.
TestCard: The company raised GBP 3.8 million of venture funding from East Post Road Ventures and other undisclosed investors on March 14, 2022, putting the company’s pre-money valuation at GBP 35.1 million. The company is a developer of a medical diagnostic technology designed to provide non-invasive at-home testing.
PolyCore Therapeutics: The company raised $4.7 million of venture funding from undisclosed investors on March 17, 2022. The company is a developer of therapies intended to treat dyskinesia and cognitive impairment associated with central nervous system disorders.
Brenus Pharma: The company raised EUR 4 million of venture funding from undisclosed investors on March 17, 2022. The company is a developer of an anti-cancer cell-based immunotherapy designed to generate allogeneic cell vaccines for the immunotherapy of solid tumors.
Lindy Biosciences: The company raised $3.3 million of venture funding from undisclosed investors on March 15, 2022. The company is a developer of advanced protein formulations designed for biotherapeutics.
Cardiawave: The company is in the process of raising Series B venture funding on March 14, 2022. The company is a developer of a non-invasive ultrasonic medical device designed to treat heart valve diseases.
Caretaker Medical: The company is in the process of raising Series B venture funding on March 15, 2022. The company is a developer of a wireless patient monitoring platform designed to connect clinicians to their patients across the full continuum of care.
Circle Cardiovascular Imaging: The company entered into a definitive agreement to receive an undisclosed amount of development capital from Thoma Bravo on March 16, 2022. The company is a developer of a cardiovascular imaging post-processing system intended to diagnose complex cardiovascular diseases.
KaliVir Immunotherapeutics: The company raised an undisclosed amount of Series A venture funding in a deal led by Premier Partners on March 16, 2022. Nextrans, Company K Partners, and QUAD Investment Management also participated in the round. The company is a developer of a novel oncolytic platform designed to enhance systemic delivery capabilities, tumor-targeted replication, and viral spread within the tumor microenvironment.
Reaction Biology: The company received an undisclosed amount of development capital from Cobepa on March 16, 2022. The company is an operator of a contract research organization providing early-stage drug discovery services to pharma, academic, and research customers.
